Moderna (MRNA) Stock: French Study Sparks Rally After FDA Shock – Latest News, Analyst Forecasts and 2026 Outlook
Updated: December 6, 2025 Moderna, Inc. (NASDAQ: MRNA) has just had one of its most dramatic weeks of 2025. Shares plunged early in the week after news that the U.S. Food and Drug Administration (FDA) may tighten vaccine approval standards, then rebounded sharply on Friday after a massive French real‑world study reaffirmed the safety and effectiveness of its COVID‑19 vaccine. Investopedia+2Investopedia+2 As of the close on Friday, December 5, Moderna stock finished at $27.70, up 8.7% on the day and trading near the middle of its 52‑week range of $22.28 to $48.92, giving the company a market capitalization of about